Therapeutic Response

CHEK2 pathogenic variants status confers therapeutic sensitivity to Enzalutamide in combination with Talazoparib in patients with Prostate Adenocarcinoma.

Statements

Source and description
Talzenna (talazoparib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).